This is a prospective, observational study to compare the changes in stool microbiome of HIV positive treatment naive or who have not been on ART for at least 6 months subjects pretreatment and 12 weeks after initiation of ART. Subjects will be recruited at the Immunology Center Clinic of Palmetto Health/ University of South Carolina located in Columbia SC.
Adults >18years with serologically documented HIV infection and no prior ART use for pre exposure or post exposure prophylaxis within the last 6 months will be included in the study
Emphysema is a type of Chronic Obstructive Pulmonary Disease (COPD) and a major cause of death. Studies suggest that emphysema is more common in HIV positive people (HIV+) compared to HIV negative (HIV-) people. The purpose of this research study is to determine whether emphysema in HIV+ patients is clinically and biologically different compared to emphysema in those without HIV.
This is a study to develop a test for radiation exposure in the event of a nuclear event such as the detonation of a nuclear device or widespread radiation exposure. We will collect blood samples from a variety of different types of human subjects whose current medical status could possibly have an effect on the results of the test, such as trauma, burns, infections or a damaged immune system or young children. The goal is to ensure that these conditions do not affect the results of the test.
This Phase 3 protocol is a randomized, double-blind, study evaluating the safety and efficacy of switching from a regimen of either dolutegravir (DTG) and emtricitabine (Emtriva®)/tenofovir alafenamide (Descovy®; F/TAF) or DTG and emtricitabine/tenofovir disoproxil fumarate (Truvada®; F/TDF) to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus DTG+F/TAF in virologically suppressed HIV-1 infected adults with or without antiretroviral resistance. Male and female HIV-1 infected patients greater than or equal to 18 years of age currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF may be eligible to participate in this study.
University of South Carolina School of Medicine
Two Medical Park, Suite 502
Columbia, SC 29203
Study Site Principal Investigator Contact Information:
Helmut Albrecht, MD at 803-540-1000
HIV testing is often shunned in community settings due to the stigma of HIV-centric services. Our recent pilot study strongly suggest that integration of a package of screening that include HIV, diabetes, and hypertension hold promise of substantially increasing the uptake of HIV testing while simultaneously providing direly needed community screening for non-communicable disease (NCDs) like diabetes and hypertension, which themselves are at epidemic levels in Sub-Saharan Africa. This study will examine whether integrating HIV screening with NCD screening will improve uptake of HIV testing and whether integrating HIV and NCD care will improve retention.
This clinical research study is looking for men and women 18 years of age or older to test and evaluate the safety and effectiveness of an investigational combination medication for adults living with HIV.
Volunteers must be diagnosed with HIV-1 and on certain treatment regimens for HIV for at least the past 3 months. Those who qualify will take study medication for at least 48 weeks (almost 1 year). This medication will either be the investigational medication or an FDA approved medication for HIV. Subjects will receive all study-related care at no cost.
HIV-related fatigue is a serious problem for those infected with the virus. We believe that cognitive behavioral stress management is a good solution since stress is the most consistent predictor of increases in fatigue for this group. We want to convert an already proven curriculum to an mHealth format to extend the reach of this intervention.
Treatment of chronic hepatitis C virus (HCV) infection is now possible with all oral medications. While most patients achieve a sustained virologic response (SVR) after treatment, synonymous with cure, some patients relapse after treatment for reasons that are unclear. The goal of this research is to understand how a person's immune system changes during treatment of HCV infection with all oral therapy, and how these changes might impact the chances of relapse after treatment. To address these questions, blood and clinical information will be collected from study participants over the course of receiving standard of care treatment for HCV infection. This blood and clinical information will be used to conduct laboratory research focused on the immune system.
Pitavastatin lowers high cholesterol and triglyceride levels in the blood. The primary purpose of this study is to determine the effects of pitavastatin on lowering the traditional risk factors for cardiological events in patients who have HIV.